| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
64,880,000 |
| Market
Cap: |
382.14(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.37 - $12.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 3.8 |
| Insider 3/6 Months : 4.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Co.'s primary program is TERN-101, a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) agonist that has demonstrated sustained liver FXR activation, as well as a favorable tolerability profile across multiple clinical trials. Co.'s another clinical stage program, TERN-201, is an inhibitor of Vascular Adhesion Protein-1. Co. is also evaluating the potential to co-administer TERN-201 in combination with a metabolically active NASH treatment.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,486 |
23,591 |
14,909,528 |
| Total Buy Value |
$0 |
$5,618 |
$36,787 |
$43,710,646 |
| Total People Bought |
0 |
2 |
3 |
7 |
| Total Buy Transactions |
0 |
2 |
5 |
24 |
| Total Shares Sold |
420,663 |
420,663 |
420,663 |
1,920,663 |
| Total Sell Value |
$2,796,859 |
$2,796,859 |
$2,796,859 |
$11,046,859 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
3 |
3 |
3 |
4 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2022-08-16 |
4 |
B |
$2.42 |
$3,630,000 |
I/I |
1,500,000 |
2,981,592 |
1.5 |
84% |
|
| Lu Hongbo |
|
– • – |
2022-08-16 |
4 |
B |
$2.42 |
$3,630,000 |
I/I |
1,500,000 |
2,981,592 |
0.01 |
84% |
|
| Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2022-08-15 |
4 |
B |
$2.99 |
$3,642 |
I/I |
1,218 |
1,481,592 |
1.42 |
103% |
|
| Lu Hongbo |
|
– • – |
2022-08-15 |
4 |
B |
$2.99 |
$3,642 |
I/I |
1,218 |
1,481,592 |
0.01 |
103% |
|
| Vivo Capital Surplus Fund Viii, L.p. |
10% Owner |
– – • |
2022-08-12 |
4 |
B |
$2.98 |
$3,346,603 |
I/I |
1,123,021 |
1,480,374 |
1.5 |
173% |
|
| Lu Hongbo |
|
– • – |
2022-08-12 |
4 |
B |
$2.98 |
$3,346,603 |
I/I |
1,123,021 |
1,480,374 |
0.01 |
173% |
|
| Vignola Mark J. |
Chief Financial Officer |
• – – |
2022-05-31 |
4 |
B |
$1.47 |
$11,254 |
D/D |
7,656 |
7,656 |
0.01 |
224% |
|
| Sundaram Senthil Vel |
Chief Executive Officer |
• • – |
2022-05-31 |
4 |
B |
$1.47 |
$11,254 |
D/D |
7,656 |
7,656 |
0.01 |
224% |
|
| Yoon Seokho Bryan |
COO and General Counsel |
• – – |
2022-05-31 |
4 |
B |
$1.47 |
$11,254 |
D/D |
7,656 |
7,656 |
0.01 |
224% |
|
| Lav Aqua Ltd |
10% Owner |
– – • |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
4,781,566 |
1,405,583 |
|
- |
|
| Vivo Opportunity Fund, L.p. |
10% Owner |
– – • |
2021-02-09 |
4 |
B |
$17.00 |
$8,075,000 |
I/I |
475,000 |
357,353 |
1.5 |
-27% |
|
| Vivo Opportunity Fund, L.p. |
10% Owner |
– – • |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
2,200,133 |
266,948 |
|
- |
|
| Gordon Carl L |
Director |
– • • |
2021-02-09 |
4 |
B |
$17.00 |
$8,075,000 |
I/I |
475,000 |
2,274,723 |
2.25 |
-27% |
|
| Gordon Carl L |
Director |
– • • |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
3,316,204 |
1,989,723 |
|
- |
|
| Orbimed Advisors Iii Ltd |
Director |
– • • |
2021-02-09 |
4 |
B |
$17.00 |
$8,075,000 |
I/I |
475,000 |
2,274,723 |
2.25 |
-27% |
|
| Orbimed Advisors Iii Ltd |
Director |
– • • |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
3,316,204 |
1,989,723 |
|
- |
|
| Deerfield Capital Lp Et Al |
Possible Member of 10% Group |
– – • |
2021-02-09 |
4 |
B |
$17.00 |
$11,305,000 |
I/I |
665,000 |
2,382,033 |
1.5 |
-27% |
|
| Deerfield Capital Lp Et Al |
Possible Member of 10% Group |
– – • |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
1,717,033 |
1,717,033 |
|
- |
|
| Zhong Weidong |
Chief Scientific OfficerOffice |
• • – |
2021-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
285,714 |
|
- |
|
44 Records found
|
|
Page 2 of 2 |
|
|
0.33 (5.94%) 
